
Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo
BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed Gentili in a deal valued at $250 million upfront. The transaction – which is due to close in October – will see BioCryst's …